An unexpected late-stage failure doesn't derail Astra
10/07/26 -"Astra’s cardiovascular drug, Wainua, failed a late-stage trial for a heart condition, and most of the drug’s $5bn peak sales expectations hinged on this trial. Considering the ..."
Pages
65
Language
English
Published on
10/07/26
You may also be interested by these reports :
10/07/26
Astra’s cardiovascular drug, Wainua, failed a late-stage trial for a heart condition, and most of the drug’s $5bn peak sales expectations hinged on ...
07/07/26
Following the June 2026 phase III R&D setback for an investigational drug, Riliprubart, targeting a rare neurological disease called CIDP (chronic ...
06/07/26
Our target price has been adjusted downward as we have removed the 20% premium associated with peer-based valuation metrics. This adjustment is due ...
30/06/26
The recent US Supreme Court decision in the Roundup litigations, went in favour of Bayer, and brings the firm very close to ending this chapter. Even ...